期刊文献+

经尿道1470nm半导体激光与TURBT治疗表浅性膀胱肿瘤的临床疗效比较 被引量:15

原文传递
导出
摘要 目的:评价经尿道1 470nm半导体激光治疗表浅性膀胱肿瘤的疗效,并与经尿道膀胱肿瘤电切术(TURBT)的疗效和安全进行比较。方法:随机选取61例膀胱肿瘤患者按手术方式分为1 470nm半导体激光组(27例)及TURBT组(34例),比较两组平均手术时间、术中出血量、闭孔神经反射发生例数、膀胱穿孔例数、术后平均住院时间及术后肿瘤复发率等指标,并比较其临床疗效。结果:两组术后平均住院时间、术后6个月肿瘤复发率的差异无统计学意义(P>0.05),术后15个月肿瘤复发率的差异有统计学意义(P<0.05);TURBT组手术时间少于半导体激光组(P<0.05);而半导体激光组的术中出血量、闭孔神经反射发生例数、膀胱穿孔例数明显少于TURBT组(P<0.05)。结论:经尿道1 470nm半导体激光治疗表浅性膀胱肿瘤与TURBT短期临床疗效相似,中期疗效更优。经尿道1 470nm激光切除膀胱肿瘤操作简单,疗效安全可靠,创伤小,术中及术后无严重并发症,是膀胱浅表性肿瘤治疗的一种理想手法,值得临床推广应用。
出处 《临床泌尿外科杂志》 2015年第12期1132-1134,共3页 Journal of Clinical Urology
  • 相关文献

参考文献9

  • 1Ploeg M, Aben K K, Kiemeney L A. The present and future burden of urinary bladder cancer in the world [J]. WorldJ Urol, 2009, 27(3): 289--293.
  • 2Jemal A, Siegel R, Xu J. Cancer statistics[J]. CA_ Cancer J Clin, 2010, 60(5): 277--300.
  • 3Yavari N, Andersson-Engels S, Segersten U, et al. An overview on preclinical and clinical experiences with photodynamic therapy for bladder cancer[J]. Can J Urol, 2011, 18(4): 5778-5786.
  • 4Sexton W J, Wiegand L R, Correa J J, et al. Bladder cancer: a review of non-muscle invasive disease[J]. Cancer Control, 2010, 17(4): 256--268.
  • 5夏术阶,于胜强.激光技术在泌尿系统肿瘤治疗中的合理应用[J].现代泌尿外科杂志,2007,12(4):211-213. 被引量:14
  • 6Seitz M, Sroka R, Gratzke C, et al. The diode laser: a novel side-firing approach for laser vaporisation of the human prostate--immediate efficacy and 1-year follow- up[J]. EurUrol, 2007, 52(6): 1717--1722.
  • 7张心如,乔勇,谷宝军,冯超,谢弘,司捷旻,刘章顺,刘莺.肿瘤危险因素评分对非肌层浸润性膀胱肿瘤预后判断的价值(附248例报告)[J].临床泌尿外科杂志,2011,26(12):930-933. 被引量:4
  • 8王中新.经尿道电切联合选择性钬激光治疗膀胱表浅性肿瘤50例[J].中国综合临床,2014,(z1):80-81.
  • 9Bai Y, Liu L, Yuan H, et al. Safety and efficacy of transurethral laser therapy for bladder cancer: a sys- tematic review and meta-analysis[J]. World J Surg On- col, 2014, 12: 301.

二级参考文献43

  • 1夏术阶,孙晓文,朱江,鲁军,凡杰,朱轶勇.经尿道钬激光局部膀胱壁切除治疗肌层浸润膀胱肿瘤[J].中华泌尿外科杂志,2005,26(5):352-352. 被引量:27
  • 2夏术阶,张沂南,鲁军,孙晓文,张捷,朱轶勇,李维国.铥激光“剥橘”式切除术治疗良性前列腺增生症[J].中华医学杂志,2005,85(45):3225-3228. 被引量:95
  • 3Kaufman D S, Shipley W U, Feldman A S. Bladder cancer[J]. Lancet, 2009, 374(9685):239-249.
  • 4Broden L S Jr, Clark P E, Hall M C. Bladder cancer [J]. Curr OpinOncol, 2005, 17:275-280.
  • 5Babjuk M, Oosterlinck W, Sylvester R, et al. European Association of Urology (EAU). EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder[J]. Eur Urol, 2008, 54(2):303-314.
  • 6Messing E M. Urothelial tumors of the urinary tract [M]. In: Walsh P C, Retik A B, Vaughan E D Jr, et al. eds. Campbell's urology. 8th ed. Philadelphia (PA): W. B. Saunders, 2002:2732-2784.
  • 7Epstein J I, Amin M B, Reuter V R, et al. The World Health Organization/International society of urological pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary blad- der. Bladder Consensus Conference Committee[J]. Am J Surg Pathol, 1998, 22:1435-1448.
  • 8Heney N M, Ahmed S, Flanagan M J, etal. Super- ficial bladder cancer: progression and recurrence[J]2. J Urol, 1983, 130:1083-1086.
  • 9Lopez-Beltran A, Bassi P, Pavone-Macaluso M, et al. Handling and pathology reporting of specimens with carcinoma of the urinary bladder, ureter, and renalpelvis[J]. Eur Urol, 2004, 45(3):257-266.
  • 10Millan-Rodriguez F, Chechile-Toniolo G, Salvador- Bayarri J, et al. Primary superficial bladder cancer risk groups according to progression, mortality and recurrence[J]. J Urol, 2000, 164: 680-684.

共引文献17

同被引文献82

引证文献15

二级引证文献53

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部